240 related articles for article (PubMed ID: 31836808)
21. Quantitative reverse transcription-polymerase chain reaction measurement of HASH1 (ASCL1), a marker for small cell lung carcinomas with neuroendocrine features.
Westerman BA; Neijenhuis S; Poutsma A; Steenbergen RD; Breuer RH; Egging M; van Wijk IJ; Oudejans CB
Clin Cancer Res; 2002 Apr; 8(4):1082-6. PubMed ID: 11948117
[TBL] [Abstract][Full Text] [Related]
22. The deregulation of miR-17/CCND1 axis during neuroendocrine transdifferentiation of LNCaP prostate cancer cells.
Dankert JT; Wiesehöfer M; Czyrnik ED; Singer BB; von Ostau N; Wennemuth G
PLoS One; 2018; 13(7):e0200472. PubMed ID: 30001402
[TBL] [Abstract][Full Text] [Related]
23. Adrenomedullin, an autocrine/paracrine factor induced by androgen withdrawal, stimulates 'neuroendocrine phenotype' in LNCaP prostate tumor cells.
Berenguer C; Boudouresque F; Dussert C; Daniel L; Muracciole X; Grino M; Rossi D; Mabrouk K; Figarella-Branger D; Martin PM; Ouafik L
Oncogene; 2008 Jan; 27(4):506-18. PubMed ID: 17637748
[TBL] [Abstract][Full Text] [Related]
24. The role of high cell density in the promotion of neuroendocrine transdifferentiation of prostate cancer cells.
Pernicová Z; Slabáková E; Fedr R; Šimečková Š; Jaroš J; Suchánková T; Bouchal J; Kharaishvili G; Král M; Kozubík A; Souček K
Mol Cancer; 2014 May; 13():113. PubMed ID: 24884804
[TBL] [Abstract][Full Text] [Related]
25. Release of macrophage migration inhibitory factor by neuroendocrine-differentiated LNCaP cells sustains the proliferation and survival of prostate cancer cells.
Tawadros T; Alonso F; Jichlinski P; Clarke N; Calandra T; Haefliger JA; Roger T
Endocr Relat Cancer; 2013 Feb; 20(1):137-49. PubMed ID: 23207293
[TBL] [Abstract][Full Text] [Related]
26. MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer.
Yasumizu Y; Rajabi H; Jin C; Hata T; Pitroda S; Long MD; Hagiwara M; Li W; Hu Q; Liu S; Yamashita N; Fushimi A; Kui L; Samur M; Yamamoto M; Zhang Y; Zhang N; Hong D; Maeda T; Kosaka T; Wong KK; Oya M; Kufe D
Nat Commun; 2020 Jan; 11(1):338. PubMed ID: 31953400
[TBL] [Abstract][Full Text] [Related]
27. Androgen-responsive and -unresponsive prostate cancer cell lines respond differently to stimuli inducing neuroendocrine differentiation.
Marchiani S; Tamburrino L; Nesi G; Paglierani M; Gelmini S; Orlando C; Maggi M; Forti G; Baldi E
Int J Androl; 2010 Dec; 33(6):784-93. PubMed ID: 20088946
[TBL] [Abstract][Full Text] [Related]
28. Conditionally Reprogrammed Cells from Patient-Derived Xenograft to Model Neuroendocrine Prostate Cancer Development.
Ci X; Hao J; Dong X; Xue H; Wu R; Choi SYC; Haegert AM; Collins CC; Liu X; Lin D; Wang Y
Cells; 2020 Jun; 9(6):. PubMed ID: 32512818
[TBL] [Abstract][Full Text] [Related]
29. Neuroendocrine Transdifferentiation in Human Prostate Cancer Cells: An Integrated Approach.
Cerasuolo M; Paris D; Iannotti FA; Melck D; Verde R; Mazzarella E; Motta A; Ligresti A
Cancer Res; 2015 Aug; 75(15):2975-86. PubMed ID: 26069250
[TBL] [Abstract][Full Text] [Related]
30. Heterochromatin Protein 1α Mediates Development and Aggressiveness of Neuroendocrine Prostate Cancer.
Ci X; Hao J; Dong X; Choi SY; Xue H; Wu R; Qu S; Gout PW; Zhang F; Haegert AM; Fazli L; Crea F; Ong CJ; Zoubeidi A; He HH; Gleave ME; Collins CC; Lin D; Wang Y
Cancer Res; 2018 May; 78(10):2691-2704. PubMed ID: 29487201
[TBL] [Abstract][Full Text] [Related]
31. Androgen deprivation-induced ZBTB46-PTGS1 signaling promotes neuroendocrine differentiation of prostate cancer.
Chen WY; Zeng T; Wen YC; Yeh HL; Jiang KC; Chen WH; Zhang Q; Huang J; Liu YN
Cancer Lett; 2019 Jan; 440-441():35-46. PubMed ID: 30312731
[TBL] [Abstract][Full Text] [Related]
32. Regulation of neuroendocrine differentiation by AKT/hnRNPK/AR/β-catenin signaling in prostate cancer cells.
Ciarlo M; Benelli R; Barbieri O; Minghelli S; Barboro P; Balbi C; Ferrari N
Int J Cancer; 2012 Aug; 131(3):582-90. PubMed ID: 22015967
[TBL] [Abstract][Full Text] [Related]
33. Androgen and taxol cause cell type-specific alterations of centrosome and DNA organization in androgen-responsive LNCaP and androgen-independent DU145 prostate cancer cells.
Schatten H; Ripple M; Balczon R; Weindruch R; Chakrabarti A; Taylor M; Hueser CN
J Cell Biochem; 2000 Jan; 76(3):463-77. PubMed ID: 10649443
[TBL] [Abstract][Full Text] [Related]
34. Phthalates deregulate cell proliferation, but not neuroendocrine transdifferentiation, in human LNCaP prostate cancer cell model.
Hrubá E; Pernicová Z; Pálková L; Souček K; Vondráček J; Machala M
Folia Biol (Praha); 2014; 60 Suppl 1():56-61. PubMed ID: 25369342
[TBL] [Abstract][Full Text] [Related]
35. Molecular model for neuroendocrine prostate cancer progression.
Chen R; Dong X; Gleave M
BJU Int; 2018 Oct; 122(4):560-570. PubMed ID: 29569310
[TBL] [Abstract][Full Text] [Related]
36. Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-Resistant Prostate Cancer.
Zou M; Toivanen R; Mitrofanova A; Floch N; Hayati S; Sun Y; Le Magnen C; Chester D; Mostaghel EA; Califano A; Rubin MA; Shen MM; Abate-Shen C
Cancer Discov; 2017 Jul; 7(7):736-749. PubMed ID: 28411207
[TBL] [Abstract][Full Text] [Related]
37. 6-(3,4-Dihydro-1H-isoquinoline-2-yl)-N-(6-methoxypyridine-2-yl) nicotinamide-26 (DIMN-26) decreases cell proliferation by induction of apoptosis and downregulation of androgen receptor signaling in human prostate cancer cells.
Choi HE; Shin JS; Leem DG; Kim SD; Cho WJ; Lee KT
Chem Biol Interact; 2016 Dec; 260():196-207. PubMed ID: 27720946
[TBL] [Abstract][Full Text] [Related]
38. Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: implications for prostate cancer progression.
Cox ME; Deeble PD; Lakhani S; Parsons SJ
Cancer Res; 1999 Aug; 59(15):3821-30. PubMed ID: 10447001
[TBL] [Abstract][Full Text] [Related]
39. Shutdown of achaete-scute homolog-1 expression by heterogeneous nuclear ribonucleoprotein (hnRNP)-A2/B1 in hypoxia.
Kasim M; Benko E; Winkelmann A; Mrowka R; Staudacher JJ; Persson PB; Scholz H; Meier JC; Fähling M
J Biol Chem; 2014 Sep; 289(39):26973-26988. PubMed ID: 25124043
[TBL] [Abstract][Full Text] [Related]
40. Human ASH1 expression in prostate cancer with neuroendocrine differentiation.
Rapa I; Ceppi P; Bollito E; Rosas R; Cappia S; Bacillo E; Porpiglia F; Berruti A; Papotti M; Volante M
Mod Pathol; 2008 Jun; 21(6):700-7. PubMed ID: 18311112
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
